TL;DR: UnitedHealthcare modified its Tier 2 Molecular Pathology Procedures coverage policy for Medicare Advantage, effective February 2, 2026. If your lab or practice bills CPT codes 81400–81408, this update changes how UHC evaluates medical necessity — and ties coverage directly to local coverage determinations that vary by state.
UnitedHealthcare updated the tier-2-molecular-pathology-procedures policy governing CPT codes 81400 through 81408 for Medicare Advantage members. The change refines coverage criteria, codifies the relationship between Tier 2 codes and NGS panels, and explicitly directs billers to local coverage determinations (LCDs) for state-specific rules. If your team bills molecular pathology under Medicare Advantage, this policy is now the rulebook.
| Field | Detail |
|---|---|
| Payer | UnitedHealthcare |
| Policy | Tier 2 Molecular Pathology Procedures – Medicare Advantage Medical Policy |
| Policy Code | tier-2-molecular-pathology-procedures |
| Change Type | Modified |
| Effective Date | February 2, 2026 |
| Impact Level | High |
| Specialties Affected | Molecular pathology, clinical laboratory, oncology, genetics, endocrinology |
| Key Action | Audit all claims billed under CPT 81400–81408 against applicable LCD requirements before submitting to UHC Medicare Advantage |
UnitedHealthcare Tier 2 Molecular Pathology Coverage Criteria and Medical Necessity Requirements 2026
The UHC tier-2-molecular-pathology-procedures coverage policy ties reimbursement to a layered set of criteria. For states and territories where no LCD or local coverage article (LCA) exists, UHC will cover Tier 2 molecular pathology procedures when all of the following conditions are met:
| # | Covered Indication |
|---|---|
| 1 | No alternative lab or clinical test can definitively diagnose the disorder, or existing results are clearly equivocal |
| 2 | A clinically valid test exists, supported by published, peer-reviewed medical literature |
| 3 | The test assay is FDA-approved, FDA-cleared, an FDA-modified test, or a lab-developed test (LDT) with documented analytical validity and clinical utility |
| 4 | Test results directly affect treatment or management of the member |
| 5 | For panels — including multiple genes or multiple conditions — testing is reasonable and necessary, and a tiered approach was used where clinically available |
Each of these is a hard requirement, not a checklist where three out of five is good enough. Miss any one, and you're looking at a claim denial.
Where LCDs and LCAs do exist — and many do — UHC defers to those policies. Medicare does not have a National Coverage Determination (NCD) for Tier 2 molecular pathology. That means Medicare Administrative Contractors set the rules in their jurisdictions. Your coverage policy analysis has to start with the LCD for your MAC region before you apply UHC's criteria.
The medical necessity bar here is high. UHC is not covering these tests for exploratory purposes. The test result has to change what you do clinically. Document that connection explicitly in the medical record.
Prior authorization requirements are not universally specified in this policy — but that doesn't mean prior auth is off the table. Check the member's specific plan benefit design. Medicare Advantage plans have authority to impose prior authorization requirements beyond what the base policy states. If you're not confirming prior auth status before ordering these tests, you're leaving reimbursement to chance.
UnitedHealthcare Tier 2 Molecular Pathology Exclusions and Non-Covered Indications
This is where the policy gets blunt. UHC lists several clinical applications that explicitly may not meet Medicare benefit category requirements or the reasonable-and-necessary threshold. Billing these indications under Medicare Advantage is a path to denial.
Non-covered or high-risk indications include:
| # | Excluded Procedure |
|---|---|
| 1 | Disease risk assessment — testing to predict future disease in a healthy member |
| 2 | Carrier screening — identifying carriers of heritable conditions |
| 3 | Hereditary cancer syndrome testing — this one is nuanced. Some hereditary cancer tests are covered under specific LCDs, but the base UHC policy flags this as potentially non-covered |
| 4 | Gene expression profiling for certain cancers — "certain" is doing a lot of work here; check the applicable LCD |
| 5 | Prenatal diagnostic testing — rarely meets Medicare benefit criteria for obvious demographic reasons |
| 6 | Diagnosis and monitoring of non-cancer indications — again, LCD-dependent |
The non-covered ICD-10 diagnosis codes in this policy include anesthesia-related adverse effects and underdosing codes (T41.0X5A through T41.1X6S). If any of those codes appear as the primary diagnosis on a Tier 2 molecular pathology claim, the claim will not be covered.
There's also a critical NGS rule. Tier 2 individual biomarker CPT codes — 81400 through 81408 — cannot be used for a single gene or any combination of genes when testing is performed as part of an NGS or other multiplexing technology panel. If you ran the test on an NGS platform, billing it as a Tier 2 individual code is a coding error. It will either get denied or create audit exposure. Use the appropriate NGS CPT codes instead.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Molecular pathology with no alternative diagnostic test available | Covered (if all criteria met) | 81400–81408 | Must document that alternatives were unavailable or equivocal |
| Testing with FDA-approved/cleared assay or validated LDT | Covered (if all criteria met) | 81400–81408 | Analytical validity documentation required |
| Results directly change treatment or management | Covered (if all criteria met) | 81400–81408 | Clinical utility must be documented in the record |
| Multi-gene panels with tiered testing approach | Covered (if criteria met) | 81400–81408 | Tiered approach must be clinically available and used |
| Testing performed via NGS or multiplexing platform | Not Covered under 81400–81408 | 81400–81408 | Bill under appropriate NGS codes, not Tier 2 individual codes |
| Disease risk assessment | Not Covered | 81400–81408 | Does not meet Medicare reasonable-and-necessary threshold |
| Carrier screening | Not Covered | 81400–81408 | Does not meet Medicare benefit category |
| Prenatal diagnostic testing | Not Covered | 81400–81408 | Rarely applicable to Medicare population |
| Hereditary cancer syndromes | LCD-Dependent | 81400–81408 | Check applicable MAC LCD before billing |
| Gene expression profiling for certain cancers | LCD-Dependent | 81400–81408 | Covered under specific LCDs only |
| Non-cancer diagnosis and monitoring | LCD-Dependent | 81400–81408 | LCD governs; base policy does not cover |
| Bladder malignancy (C67.0–C67.8) | LCD-Dependent | 81406 | Check LCD for specific gene analyte requirements |
| Thyroid malignancy (C73) | LCD-Dependent | 81405–81406 | Verify applicable MAC LCD |
| Adrenal medulla malignancy (C74.10–C74.12) | LCD-Dependent | 81404–81405 | RET gene variants — check RET MEN Type 2 LCD criteria |
| Parathyroid malignancy or benign neoplasm (C75.0, D35.1) | LCD-Dependent | 81406 | ATP7B applies to D35.1; verify LCD |
| Wilson's disease (E83.01) | LCD-Dependent | 81406 | ATP7B — requires peer-reviewed clinical validity documentation |
| Anesthesia adverse effects / underdosing (T41.0X5A–T41.1X6S) | Not Covered | 81400–81408 | Listed as non-covered primary diagnosis codes |
UnitedHealthcare Molecular Pathology Billing Guidelines and Action Items 2026
The effective date of February 2, 2026 has passed. If you haven't already adjusted your workflow, do it now.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's LCDs for Tier 2 molecular pathology before every claim submission. UHC defers to LCDs where they exist. The Medicare Coverage Database is your first stop. Billing without checking the applicable LCD is the single biggest claim denial risk in this policy. |
| 2 | Stop billing 81400–81408 for NGS-based testing. If the lab ran the test on a next-generation sequencing platform or any multiplexing technology, Tier 2 individual codes are wrong. Recode to the appropriate NGS CPT codes. Audit any claims submitted since February 2, 2026 that used 81400–81408 for NGS-performed tests. |
| 3 | Verify the analyte-to-code match for every claim. The Tier 2 levels (81400 through 81408) are defined by technical resources and interpretive work, not by diagnosis alone. The specific gene or analyte being tested must appear in the CPT code descriptor for that level. If the analyte isn't listed under any Tier 2 code or Tier 1 code, you must use a Not Otherwise Classified (NOC) code — not the closest-sounding Tier 2 code. |
| 4 | Document clinical utility explicitly in the medical record. UHC requires that test results directly affect treatment or management. A lab report sitting in the chart is not enough. The ordering provider needs to document why the test was ordered and how the result will be used. Without that, you don't have medical necessity — you have a test. |
| 5 | Check prior authorization requirements at the plan level. This policy doesn't mandate prior auth universally, but individual Medicare Advantage plan benefit designs can. Call UHC or check the plan benefits before the test is ordered. Retroactive auth is nearly impossible to get, and without it, your molecular pathology billing hits a wall. |
| 6 | Flag hereditary cancer, gene expression, and non-cancer indications for clinical review before billing. These fall into an LCD-dependent gray zone. Run them by your compliance officer or billing consultant before submitting. If your compliance officer isn't already tracking your MAC's LCD update cycle for molecular pathology, that's a gap worth closing. |
| 7 | Do not bill full gene sequencing codes unless the assay performed was a full gene sequence. This sounds obvious, but it's a common coding error. If the code descriptor says "full gene sequence" and the test assay was a targeted variant analysis, you're overcoding. The reverse is also true — don't use variant-specific codes when full sequencing was performed. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Tier 2 Molecular Pathology Under tier-2-molecular-pathology-procedures
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 81400 | CPT | Molecular pathology procedure, Level 1 |
| 81401 | CPT | Molecular pathology procedure, Level 2 |
| 81402 | CPT | Molecular pathology procedure, Level 3 |
| 81403 | CPT | Molecular pathology procedure, Level 4 |
| 81404 | CPT | Molecular pathology procedure, Level 5 |
| 81405 | CPT | Molecular pathology procedure, Level 6 |
| 81406 | CPT | Molecular pathology procedure, Level 7 |
| 81407 | CPT | Molecular pathology procedure, Level 8 |
| 81408 | CPT | Molecular pathology procedure, Level 9 |
Coverage for each code depends on the specific analyte listed in the CPT descriptor, the applicable LCD for your MAC region, and whether all UHC medical necessity criteria are satisfied.
Key ICD-10-CM Diagnosis Codes
Covered / LCD-Dependent Diagnoses
| Code | Description |
|---|---|
| C67.0 | Malignant neoplasm of trigone of bladder |
| C67.1 | Malignant neoplasm of dome of bladder |
| C67.2 | Malignant neoplasm of lateral wall of bladder |
| C67.3 | Malignant neoplasm of anterior wall of bladder |
| C67.4 | Malignant neoplasm of posterior wall of bladder |
| C67.5 | Malignant neoplasm of bladder neck |
| C67.6 | Malignant neoplasm of ureteric orifice |
| C67.7 | Malignant neoplasm of urachus |
| C67.8 | Malignant neoplasm of overlapping sites of bladder (note: CPT 81406 for RYR1) |
| C73 | Malignant neoplasm of thyroid gland |
| C74.10 | Malignant neoplasm of medulla of unspecified adrenal gland |
| C74.11 | Malignant neoplasm of medulla of right adrenal gland |
| C74.12 | Malignant neoplasm of medulla of left adrenal gland |
| C75.0 | Malignant neoplasm of parathyroid gland |
| D35.1 | Benign neoplasm of parathyroid gland (note: CPT 81406 for ATP7B) |
| E83.01 | Wilson's disease |
Non-Covered Primary Diagnosis Codes
These codes, when listed as the primary diagnosis, result in no coverage for Tier 2 molecular pathology procedures under this policy.
| Code | Description |
|---|---|
| T41.0X5A | Adverse effect of inhaled anesthetics, initial encounter |
| T41.0X5D | Adverse effect of inhaled anesthetics, subsequent encounter |
| T41.0X5S | Adverse effect of inhaled anesthetics, sequela |
| T41.0X6A | Underdosing of inhaled anesthetics, initial encounter |
| T41.0X6D | Underdosing of inhaled anesthetics, subsequent encounter |
| T41.0X6S | Underdosing of inhaled anesthetics, sequela |
| T41.1X5A | Adverse effect of intravenous anesthetics, initial encounter |
| T41.1X5D | Adverse effect of intravenous anesthetics, subsequent encounter |
| T41.1X5S | Adverse effect of intravenous anesthetics, sequela |
| T41.1X6A | Underdosing of intravenous anesthetics, initial encounter |
| T41.1X6D | Underdosing of intravenous anesthetics, subsequent encounter |
| T41.1X6S | Underdosing of intravenous anesthetics, sequela (note: CPT 81404 and 81405 for RET – MEN Type 2) |
One more note on the ICD-10 pairing: CPT 81404 and 81405 are specifically linked to RET gene testing for MEN Type 2 syndrome in this policy. If you're billing those codes, the diagnosis codes should reflect the clinical context — adrenal, thyroid, or parathyroid malignancy, not anesthesia-related codes.
Get the Full Picture for CPT 81400
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.